Febuxostat
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Febuxostat |
| DrugBank ID | DB04854 |
| Brand Names (EU) | Febuxostat Krka |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 100.00% |
Approved Indication (EMA)
Febuxostat Krka is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis). Febuxostat Krka is indicated in adults.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | obsolete hyperuricemia (disease) | 100.00% | DL |
| 2 | hypouricemia, renal | 99.99% | DL |
| 3 | hypoxanthine guanine phosphoribosyltransferase partial deficiency | 99.98% | DL |
| 4 | Lesch-Nyhan syndrome | 99.68% | DL |
| 5 | primitive portal vein thrombosis | 91.89% | DL |
| 6 | early-onset familial noncirrhotic portal hypertension | 91.89% | DL |
| 7 | hepatoportal sclerosis | 91.89% | DL |
| 8 | idiopathic copper-associated cirrhosis | 91.89% | DL |
| 9 | hepatopulmonary syndrome | 91.89% | DL |
| 10 | hepatic porphyria | 91.21% | DL |
| 11 | disorder of phenylalanine metabolism | 79.04% | DL |
| 12 | disorder of tyrosine metabolism | 77.22% | DL |
| 13 | teratogenic Pierre Robin syndrome | 77.16% | DL |
| 14 | cholelithiasis | 70.48% | DL |
| 15 | Tay-Sachs disease, b variant | 65.26% | DL |
| 16 | tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria | 64.00% | DL |
| 17 | Wiskott-Aldrich syndrome 2 | 63.35% | DL |
| 18 | Tay-Sachs disease, B1 variant | 62.94% | DL |
| 19 | anuria | 61.59% | DL |
| 20 | alacrima, achalasia, and intellectual disability syndrome | 60.84% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.